CONVERGENT THERAPEUTICS, INC. Convertible Promissory NoteConvertible Note • February 3rd, 2021 • AIkido Pharma Inc. • Services-commercial physical & biological research • New York
This Convertible Promissory Note (this “Note”) is one in a series of convertible promissory notes (collectively, the “Notes”) issued by the Company pursuant to that certain Amended and Restated Convertible Promissory Note Purchase Agreement, dated as of January 29, 2021, by and among the Company and the parties thereto (as amended through the date hereof and as may be amended or otherwise modified from time to time, the “Purchase Agreement”). As used in this and any other Notes, “Requisite Holders” shall mean the holders of a majority of the aggregate outstanding principal amount of this and such other Notes, including any holder of at least [XXX] aggregate then-outstanding principal amount of Notes. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Purchase Agreement.
AMENDED AND RESTATED CONVERTIBLE PROMISSORY NOTE PURCHASE AGREEMENTConvertible Promissory Note Purchase Agreement • February 3rd, 2021 • AIkido Pharma Inc. • Services-commercial physical & biological research • New York
THIS AMENDED AND RESTATED CONVERTIBLE PROMISSORY NOTE PURCHASE AGREEMENT (as amended through the date hereof and as may be amended or otherwise modified from time to time, this “Agreement”), is made as of the 29th day of January, 2021 by and among Convergent Therapeutics, Inc., a Delaware corporation (the “Company”), and the investors who become party hereto from time to time upon execution of a counterpart signature page (the “Purchaser Signature Page”) in substantially the form attached hereto as Exhibit A (each a “Purchaser” and collectively, the “Purchasers”).
